Grandeur Peak Global Advisors LLC Buys New Shares in Haemonetics Corporation $HAE

Grandeur Peak Global Advisors LLC bought a new position in shares of Haemonetics Corporation (NYSE:HAE) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 13,185 shares of the medical instruments supplier’s stock, valued at approximately $989,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HAE. Kemnay Advisory Services Inc. acquired a new position in shares of Haemonetics during the 4th quarter valued at about $26,000. Leonteq Securities AG acquired a new stake in shares of Haemonetics in the fourth quarter worth approximately $30,000. EverSource Wealth Advisors LLC boosted its position in shares of Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 396 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in Haemonetics in the fourth quarter valued at approximately $34,000. Finally, Kelleher Financial Advisors acquired a new position in Haemonetics during the second quarter worth approximately $38,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics News Roundup

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Zacks raised its FY2027 EPS forecast to $5.27 from $5.20, increased Q4 2027 expectations to $1.46 from $1.42, and lifted its Q1 2029 estimate to $1.41 from $1.33. The FY2029 forecast also edged up to $6.20 from $6.19, signaling somewhat stronger longer-term earnings potential. Haemonetics analyst estimates
• Neutral Sentiment: Zacks maintained forecasts of $5.67 EPS for FY2028 and $1.50 EPS for Q3 2028. Its current-year consensus estimate remains approximately $5.28–$5.29 per share, leaving the immediate earnings outlook broadly unchanged.
• Negative Sentiment: The research firm reduced estimates for several periods, including Q2 2027 EPS to $1.30 from $1.32, Q3 2027 to $1.36 from $1.37, Q1 2028 to $1.27 from $1.31, Q2 2028 to $1.44 from $1.45, Q3 2028 to $1.50 from $1.52, and FY2028 to $5.67 from $5.69. These cuts, particularly to nearer-term 2027–2028 results, likely contributed to the weaker trading despite the longer-term increases.

Analysts Set New Price Targets

A number of equities analysts have weighed in on HAE shares. BTIG Research lifted their price target on shares of Haemonetics from $96.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Raymond James Financial reissued an “outperform” rating and set a $105.00 price target on shares of Haemonetics in a research report on Friday, August 7th. Barrington Research raised their price objective on shares of Haemonetics from $95.00 to $118.00 and gave the stock an “outperform” rating in a report on Wednesday, August 19th. Citigroup upped their target price on shares of Haemonetics from $79.00 to $92.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Finally, Weiss Ratings raised shares of Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $97.56.

Haemonetics Price Performance

Shares of NYSE HAE opened at $105.04 on Friday. Haemonetics Corporation has a 1-year low of $47.31 and a 1-year high of $109.57. The company has a debt-to-equity ratio of 1.40, a current ratio of 3.08 and a quick ratio of 1.91. The business’s fifty day moving average price is $84.30 and its two-hundred day moving average price is $69.72. The firm has a market capitalization of $4.78 billion, a PE ratio of 51.49, a P/E/G ratio of 2.13 and a beta of 0.52.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%.The company had revenue of $339.38 million for the quarter, compared to analysts’ expectations of $327.86 million. During the same period last year, the business posted $1.10 earnings per share. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. On average, research analysts expect that Haemonetics Corporation will post 5.29 EPS for the current year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.